1.	Phase IV Study of Epoetin alfa in Women With Stage I, II, or III Breast Cancer and Chemotherapy-Related Anemia Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0011004, ORTHO-PR-00-27-012, ORTHO-PR-01-27-003, NCI-G01-2002, NCT00022386
2.	A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR003541, NCT00216541
3.	A Study of the Management of Blood Loss in Patients Undergoing Surgical Removal of Tumors Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR003460, NCT00264095
4.	Phase IIIB Open-Label, Controlled, Randomized Study to Identify a Single Subcutaneous Dose of PROCRIT (Epoetin alfa) That Can Be Given Weekly Rather Than the Standard Three-Times-Weekly Dose for the Treatment of Anemia in Cancer Subjects Receiving Platinum-Containing Chemotherapy (Summary Last Modified 05/98) Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RWJPRI-EPO-CA-480, NCI-V96-0978
5.	Phase III Randomized Study of Epoetin alfa With or Without Filgrastim (G-CSF) Versus Standard Transfusion Support in Patients With Myelodysplastic Syndromes Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-1996, E1996, NCT00003138
6.	Phase III Randomized Study of Epoetin Alfa versus Placebo in Anemic Patients Receiving Chemotherapy for Stage IV Metastatic Breast Cancer (Summary Last Modified 02/1999) Phase: Phase III Type: Supportive care Status: Completed Age: 18-80 Sponsor: NCI Protocol IDs: RPCI-DS-97-10, ORTHO-PR-96-27-004, NCI-G98-1394
7.	Phase III Randomized Study of Epoetin Alfa in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Chemotherapy Related Mild or Moderate Anemia Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-97125, ORTHO-PR-96-27-031, RPCI-DS-97-38, NCI-G98-1436, NCT00003341
8.	Phase III Randomized Study of Epoetin Alfa in Anemic Patients with Advanced Cancer Undergoing Chemotherapy Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-979253, NCI-P98-0133, 97-92-53, NCT00003600
9.	Phase III Randomized Study of Radiotherapy With or Without Epoetin alfa in Anemic Patients With Squamous Cell Carcinoma of the Head and Neck Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-9903, RTOG-DEV-1008, NCT00004917, RTOG-99-03
10.	Phase III Randomized Study of Adjuvant Cyclophosphamide, Epirubicin, and Fluorouracil Versus Cyclophosphamide, Epirubicin, Filgrastim (G-CSF), and Epoetin Alfa Followed By Paclitaxel Versus Cyclophosphamide and Doxorubicin Followed By Paclitaxel in Premenopausal or Early Postmenopausal Women With Previously Resected Node Positive or High-Risk Node Negative Stage I-IIIB Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 60 and under Sponsor: Pharmaceutical / Industry Protocol IDs: CAN-NCIC-MA21, AMGEN-CAN-NCIC-MA21, NCCTG-CAN-NCIC-MA21, BMS-CAN-NCIC-MA21, JANSSEN-ORTHO-CAN-NCIC-MA21, PFIZER-CAN-NCIC-MA21, NCIC-MA21, NCT00014222, SWOG-CAN-NCIC-MA21, MA21
11.	Phase III Randomized Study of Radiotherapy and Cisplatin With or Without Epoetin alfa in Patients With Cervical Cancer and Anemia Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: GOG-0191, CAN-NCIC-CX4, NCT00017004, CX4
12.	Phase III Randomized Study of Radiotherapy With or Without Adjuvant Epoetin alfa in Patients With Squamous Cell Head and Neck Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: EORTC-22996, ARO-EORTC-22996, EORTC-HN-22996, GORTEC-EORTC-22996, TROG-EORTC-22996, RHOG-EORTC-22996, GELCB-EORTC-22996, NCT00017277
13.	Phase III Randomized Study of Chemoradiotherapy With or Without Epoetin Alfa in Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CCCWFU-62299, CCCWFU-BG01-193, NCI-P01-0200, NCT00028938
14.	Phase III Randomized Study of Darbepoetin alfa Versus Epoetin alfa for Anemia in Patients With Non-Myeloid Malignancies Receiving Chemotherapy Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0201098, NCI-G02-2112, AMGEN-200101101, NCT00046982
15.	Phase III Randomized Study of Epoetin alfa in Anemic Patients With Nonmyeloid Cancer Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N02C2, NCT00058331
16.	Phase III Randomized Study of Epoetin alfa With or Without Dexamethasone for the Treatment of Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1Z01, E1Z01, NCT00060398
17.	Phase III Randomized Study of Darbepoetin alfa Versus Epoetin alfa for Anemia in Patients With Non-Myeloid Malignancies Receiving Chemotherapy Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0306021, AMGEN-20030125, NCT00070382
18.	An Efficacy and Safety Study for Epoetin Alfa (PROCRIT®) in Cancer Patients Not Receiving Chemotherapy or Radiation Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR003223, NCT00210587
19.	Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome Phase: Phase III Type: Treatment Status: Closed Age: 19 to 80 Sponsor: Other Protocol IDs: OEGRO54, NCT00348738
20.	Phase I/II Study of Escalating IL-6 with GM-CSF/EPO for Myelodysplastic Syndrome (Summary Last Modified 03/97) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: RPMI-DS-9429, NCI-T94-0072D, T94-0072
21.	Phase I/II Randomized Pilot Study of G-CSF with vs without EPO in Sequential Intensified Regimens of CAE (CTX/DOX/VP-16), HIPE (High-Dose CDDP/VP-16), and PARE (CBDCA/VP-16)/ABMT Followed by IFN-A in Children with Advanced Neuroblastoma (Summary Last Modified 08/00) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 1 and over Sponsor: NCI Protocol IDs: SJCRH-NB-91, NCI-T91-0217D, T91-0217
22.	Phase II Study of VIP/VB (VBL/IFF/CDDP/VP-16/BLEO) with G-CSF and EPO in Male Patients with Advanced Germ Cell Tumors (Summary Last Modified 09/94) Phase: Phase II Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: E-1893, E1893
23.	Phase II Study of EPO with Radiotherapy and CDDP for Stage IIB/III/IVA Cervical Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: adult Sponsor: NCI Protocol IDs: SWOG-9318
24.	Phase II Randomized Study of Paclitaxel, Fluorouracil and Hydroxyurea with Concomitant Hyperfractionated Radiotherapy with or without Epoetin alfa for Advanced Oral, Pharynx and Larynx Cancer (Summary Last Modified 06/1999) Phase: Phase II Type: Treatment Status: Closed Age: not specified Sponsor: NCI Protocol IDs: UCCRC-8626, NU-V97N1, NCI-G97-1284
25.	Phase II Study of Amifostine With or Without Epoetin Alfa in Patients with Myelodysplastic Syndromes at Relatively Low Risk of Developing Acute Leukemia Phase: Phase II Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: EORTC-06975, NCT00003681